Comparison guide

MDMA vs Ketamine

Esketamine has a Food and Drug Administration (FDA) label for treatment-resistant depression and ketamine is Schedule III, while MDMA is Schedule I with trial-stage evidence for post-traumatic stress disorder (PTSD).

Neither compound is a drop-in substitute for the other. At Mind Medicine Law, we compared the federal schedule listings, the Spravato label and the phase 3 MDMA trial paper (MAPP2) side by side. The choice follows your diagnosis and the legal route open to you.

Esketamine (Spravato) is prescribed under the FDA label and a REMS at certified settings. Ketamine other than Spravato used for depression is off-label, and a prescriber decides. MDMA is Schedule I and investigational in the cited trial. No FDA-approved MDMA product appears in the sources reviewed, so check Drugs@FDA for current status.

Table note: The two trials study different conditions on different scales against different comparators for different durations, so the figures cannot be ranked.

AttributeMDMAKetamine and esketamine (Spravato)
Federal scheduleSchedule I under 21 Code of Federal Regulations (CFR) 1308.11(d)(11) as a hallucinogenic substance (Drug Enforcement Administration (DEA) code 7405)Schedule III under 21 CFR 1308.13(c)(7) as a depressant (DEA code 7285)
FDA-approved product for this useNone in the sources reviewedEsketamine nasal spray (Spravato) approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior in adults
Condition studied in the cited trialModerate to severe PTSDTreatment-resistant depression (TRD) in adults aged 18 to under 65
Headline trial resultIn MAPP2 (NCT04077437, n=104, 18 weeks), MDMA-assisted therapy (MDMA-AT, n=53) showed a least-squares (LS) mean change of -23.7 on the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5) versus -14.8 for placebo with therapy (n=51), a treatment difference of -8.9 (P<0.001, Cohen's d=0.7)In Study 1 (NCT02418585, 4 weeks), Spravato plus oral antidepressant (n=114) showed a -19.8 LS mean change on the Montgomery-Asberg Depression Rating Scale (MADRS) versus -15.8 for placebo spray plus oral antidepressant (n=109), a treatment difference of -4.0 (95% confidence interval (CI) -7.3 to -0.6)
Session format and supervisionMDMA-assisted therapy delivered with therapy in the MAPP2 trial at 13 sites (11 US, 2 Israel)Outpatient administration with direct medical monitoring for at least 2 hours post-dose in a certified REMS healthcare setting
Safety signals in the cited sourceIn MAPP2, 98.1% had treatment-emergent adverse events (TEAEs). Severe TEAEs occurred in 9.4% (MDMA-AT) versus 3.9% (placebo). Blood pressure and pulse rose temporarily. There were no deaths or serious TEAEs.Boxed warning on Spravato label for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors
Legal access routeSchedule I under 21 CFR 1308.11(d)(11), with no prescribing route outside the investigational trial setting in the sources reviewedKetamine is Schedule III under 21 CFR 1308.13(c)(7). Spravato is dispensed only at REMS-certified settings.

Esketamine is approved for treatment-resistant depression in adults, and patients receive Spravato in certified healthcare settings under healthcare provider observation. MDMA is evaluated as MDMA-assisted therapy for moderate to severe PTSD.

Federal drug scheduling creates the primary legal divide between these two compounds.

MDMA sits in Schedule I under 21 CFR 1308.11(d)(11) with the DEA drug code 7405.

Outside FDA-regulated research, no lawful clinical access route appears in the sources reviewed.

Ketamine occupies an entirely different statutory category. Under 21 CFR 1308.13(c)(7), the federal government classifies ketamine, its salts, isomers, and salts of isomers under DEA drug code 7285 as a Schedule III depressant.

The regulatory environment also includes esketamine. The FDA approved esketamine nasal spray under the brand name Spravato. To explore how the generic formulation differs from esketamine nasal spray, read our guide on Spravato versus ketamine.

The FDA approved Spravato specifically for TRD in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. The label lists TRD in adults as monotherapy or with an oral antidepressant. It lists depressive symptoms in major depressive disorder with acute suicidal ideation or behavior only in conjunction with an oral antidepressant. Because esketamine presents risks of sedation, dissociation, and misuse, the FDA mandates distribution through a restricted distribution system known as the SPRAVATO REMS. Rules for remote prescribing of controlled medications change over time, so read ketamine legal status for the current position. State law is not covered here.

What the Clinical Evidence Covers for Each

Clinical research on MDMA and ketamine focuses on different psychiatric diagnoses, measured on different scales in separate participant populations.

MAPP2 is one of two phase 3 trials of MDMA-assisted therapy for PTSD. Mitchell and colleagues published it in Nature Medicine in 2023. This randomized, double-blind study enrolled 104 adults with moderate to severe PTSD at 13 clinical sites, 11 in the United States and 2 in Israel. The research was funded by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by the MAPS Public Benefit Corporation.

Participants in MAPP2 were tapered off psychiatric medications before baseline. Researchers randomized participants to receive either MDMA-assisted therapy (n=53) or placebo combined with identical therapy sessions (n=51). The primary outcome measure was the change in total severity score on the CAPS-5 from baseline to 18 weeks.

At the 18-week endpoint, the MDMA-AT group demonstrated an LS mean change of -23.7 on the CAPS-5 compared to -14.8 in the placebo with therapy arm. This generated a statistically significant treatment difference of -8.9 points (95% CI -13.70 to -4.12, P<0.001, Cohen's d=0.7). To explore these trial results and protocols in greater depth, review our analysis of MDMA-assisted therapy trial results and our overview of psychedelic therapy for PTSD.

The authors of MAPP2 explicitly noted that investigators cannot assume the superiority of MDMA-AT over standard selective serotonin reuptake inhibitors (SSRIs) without direct comparative trials. Furthermore, the trial excluded individuals with high current suicide risk, comorbid personality disorders, and underlying cardiovascular disease. These participant exclusions represent meaningful clinical boundaries when interpreting trial data.

Evidence for esketamine comes from registration trials documented in the FDA Spravato label. Study 1 (NCT02418585) was a 4-week, randomized, double-blind phase 3 clinical study in adults aged 18 to under 65 with treatment-resistant depression. Patients had not responded to at least two antidepressants, and the two arms had 114 and 109 patients.

In Study 1, investigators evaluated patients receiving Spravato nasal spray (56 mg or 84 mg) plus an oral antidepressant (n=114) versus placebo nasal spray plus an oral antidepressant (n=109). The primary efficacy endpoint measured change from baseline on the MADRS at the end of the 4-week treatment period. The MADRS scale ranges from 0 to 60, where higher scores reflect greater depressive severity.

At week 4, the Spravato plus oral antidepressant group achieved an LS mean reduction in MADRS total score of -19.8. The placebo nasal spray plus oral antidepressant group achieved an LS mean reduction of -15.8.

The figures cannot be ranked against each other, for four reasons:

  • Condition: PTSD and treatment-resistant depression are separate diagnoses.
  • Scale: MAPP2 used CAPS-5 and Study 1 used MADRS.
  • Comparator: MAPP2 compared MDMA-assisted therapy with placebo plus therapy, while Study 1 compared Spravato with a placebo nasal spray, with every patient also starting a daily oral antidepressant.
  • Duration: MAPP2 measured outcomes at 18 weeks and Study 1 at 4 weeks.

No head-to-head clinical trial comparing MDMA against ketamine or esketamine exists in the sources reviewed. A licensed medical provider confirms the diagnosis that guides the choice.

Safety and Monitoring Differences

The adverse event profiles of MDMA and ketamine differ, and so do the monitoring rules in the sources reviewed.

The FDA-approved label for Spravato carries a boxed warning covering:

  • Sedation
  • Dissociation
  • Respiratory depression
  • Abuse and misuse
  • Suicidal thoughts and behaviors (antidepressant class)

To manage these clinical hazards, the SPRAVATO REMS protocol mandates that healthcare facilities monitor patients for at least 2 hours following each administration. The official label instructs patients not to drive an automobile or operate heavy machinery until the next day following a restful night of sleep.

For ketamine's full risk list, see ketamine side effects.

Safety data from the MAPP2 trial of MDMA-assisted therapy revealed a different pattern of physiological and psychological risks. Across the study cohort, 98.1% of participants (102 of 104 individuals) experienced at least one treatment-emergent adverse event (TEAE). Severe TEAEs developed in 9.4% of participants (5 of 53 individuals) in the MDMA-AT group compared to 3.9% (2 of 51 individuals) in the placebo with therapy arm.

The trial documented no participant deaths and no serious treatment-emergent adverse events. The most frequent adverse events observed in the MDMA-AT group included:

  • Muscle tightness (reported by 58.5% of participants)
  • Nausea (reported by 45.3% of participants)
  • Decreased appetite (reported by 35.8% of participants)
  • Hyperhidrosis or excessive sweating (reported by 34.0% of participants)

Investigators in MAPP2 recorded temporary, dose-dependent increases in blood pressure and heart rate during MDMA sessions.

Pharmaceutical interactions are a safety consideration for MDMA protocols. In MAPP2, investigators required participants to taper off psychiatric medications before starting therapy. Patients researching pharmaceutical cross-reactions should review our guide on MDMA and SSRI interactions for detailed pharmacological context.

Supervision requirements reflect these physiological demands. Spravato administration requires 2 hours of post-dose observation in a certified medical clinic. In MAPP2, sessions were delivered with therapy at 13 study sites.

Who Neither Option Serves

Neither MDMA nor ketamine represents a universal psychiatric intervention. The Spravato label lists contraindications for aneurysmal vascular disease or arteriovenous malformation, a history of intracerebral hemorrhage, and hypersensitivity to esketamine, ketamine or any excipient. The MAPP2 trial excluded people with high current suicide risk, comorbid personality disorders and underlying cardiovascular disease, so it cannot describe risk for them.

These options do not serve individuals seeking independent home therapy, unsupervised wellness regimens, or casual self-medication. Spravato is given only under REMS supervision. Outside FDA-regulated research, no lawful clinical access route for MDMA appears in the sources reviewed.

What Would Change This Comparison

Several concrete developments would alter this comparison:

  • The FDA could grant formal market approval for an MDMA drug product, establishing a commercial label and an explicit clinical indication.
  • The DEA could reschedule MDMA from Schedule I to another controlled substance schedule under 21 CFR 1308, permitting licensed physicians to write prescriptions.
  • The FDA could modify the Spravato label or amend REMS monitoring requirements, altering clinic staffing demands and observation windows.
  • The DEA could finalize permanent telemedicine regulations, altering how prescribers evaluate patients for off-label ketamine.
  • Clinical researchers could publish a direct, randomized head-to-head trial comparing MDMA against ketamine for a single psychiatric condition using identical outcome measures.

Our Takeaway on MDMA vs Ketamine

In our side-by-side reading of the label, the schedule listings and the trial paper, ketamine-class treatment is the prescribable path today for treatment-resistant depression, with esketamine on-label under a REMS and other ketamine off-label. MDMA is Schedule I with PTSD evidence from investigational trials. The choice follows the diagnosis and licensed access. This applies to adults researching clinical options to discuss with a licensed physician. It would change if the FDA approves an MDMA product, the Spravato label or REMS changes, or a head-to-head trial in one condition on one scale appears.

Bring this MDMA vs ketamine comparison to a licensed physician or psychiatrist and ask which option matches your diagnosis and the access route open to you.

Frequently asked questions

Is ketamine more effective than MDMA for PTSD?

The sources reviewed provide no evidence that ketamine is more effective than MDMA for post-traumatic stress disorder. The MAPP2 trial evaluated MDMA-assisted therapy specifically for PTSD, while Spravato holds an FDA approval for treatment-resistant depression rather than trauma disorders. Because researchers have not conducted head-to-head clinical trials comparing these two compounds on identical clinical scales, medical science cannot rank their comparative efficacy.

Is MDMA legal for therapy?

MDMA is Schedule I under 21 CFR 1308.11(d)(11), and no FDA-approved MDMA product appears in the sources reviewed. Its post-traumatic stress disorder results come from investigational trials, and state law is not covered.

Can I get MDMA therapy outside a trial?

Outside FDA-regulated research, no lawful clinical access route for MDMA appears in the sources reviewed. State law is not covered, and a licensed attorney can answer questions about a specific situation.

Is ketamine legal?

Federal law lists ketamine in Schedule III under 21 CFR 1308.13(c)(7). Esketamine (Spravato) is on-label for treatment-resistant depression under a REMS, while ketamine other than Spravato used for depression is off-label and a prescriber decides. State law is not covered.

Is Spravato the same as ketamine?

Spravato contains esketamine. Generic ketamine formulations encompass ketamine, its salts, isomers, and salts of isomers. The FDA regulates Spravato as a prescription nasal spray under an approved label, whereas generic ketamine used for depression represents an off-label application.

Which is safer, MDMA or ketamine?

The published sources reviewed do not support a safety ranking between MDMA and ketamine because their adverse event profiles and clinical settings differ. The Spravato label carries boxed warnings for sedation, dissociation, respiratory depression, and abuse liability requiring a 2-hour clinical observation window under a REMS program. In the MAPP2 trial of MDMA-assisted therapy, 98.1% of participants experienced treatment-emergent adverse events such as muscle tightness, nausea, and temporary blood pressure elevations during sessions, but researchers reported no deaths or serious treatment-emergent adverse events.

Get psychedelic research & policy updates

New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.

Free. No spam. Unsubscribe anytime.

← Back to all therapy guides

Sources

  1. Office of the Federal Register. 21 CFR 1308.11, Schedule I (Electronic Code of Federal Regulations), paragraph (d)(11) MDMA. eCFR, Title 21, Chapter II, Part 1308, Subpart B (retrieved 17 Nov 2026), 2026. eCFR.
  2. Office of the Federal Register. 21 CFR 1308.13, Schedule III, paragraph (c)(7) ketamine (Electronic Code of Federal Regulations). eCFR, Title 21, Chapter II, Part 1308, Subpart B (retrieved 17 Nov 2026), 2026. eCFR.
  3. U.S. Food and Drug Administration / Janssen Pharmaceuticals. SPRAVATO (esketamine) nasal spray, prescribing information (label 211243s019, Reference ID 5580441). Drugs@FDA label (retrieved 17 Nov 2026), 2025. FDA label.
  4. Mitchell JM, Ot'alora G M, van der Kolk B, et al.. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine (MAPP2, NCT04077437), 2023. PMC.